CO


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 15 05 2022
revised: 30 07 2022
accepted: 15 08 2022
pubmed: 11 9 2022
medline: 19 10 2022
entrez: 10 9 2022
Statut: ppublish

Résumé

CO To evaluate the complications and the oncologic and functional outcomes of CO Retrospective analysis of 1244 consecutive laryngeal carcinomas treated with CO The mean age was 64.2 ± 11.1 years (20-96). Four hundred and sixteen patients were older than 70 years and 104 older than 80 years. The main location was the glottis (912), followed by the supraglottis (332). There were no differences in pT classification between the age groups. No differences were observed in voice outcomes. A higher rate of signs of aspiration at the glottic location was observed for those older than 70 years (2.1 % vs 5 %, p = 0.027). The need for definitive gastrostomy in supraglottic tumours was higher in those older than 70 years (0 % vs 6.5 %, p: 0.001). In the glottis, no differences in tracheostomy or gastrostomy rates were observed. Five-year overall survival was lower in the older than 70 years. No differences in disease-specific survival were observed in early stages for both locations, but a lower survival was observed in stage III glottic cancer for the older than 70 years. CO

Identifiants

pubmed: 36087502
pii: S1368-8375(22)00377-3
doi: 10.1016/j.oraloncology.2022.106088
pii:
doi:

Substances chimiques

Carbon Dioxide 142M471B3J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106088

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Isabel Vilaseca (I)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Translational Genomics and Target Therapies in Solid Tumors Group, Institut d́Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain; Head Neck Clínic, Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR 2017-SGR-01581, Barcelona, Spain. Electronic address: ivila@clinic.cat.

Francesc Xavier Avilés-Jurado (F)

Head Neck Clínic, Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR 2017-SGR-01581, Barcelona, Spain; Head Neck Section, Otorhinolaryngology Department, Hospital Universitari Joan XXIII de Tarragona, Spain; Institut d'Investigació Sanitària Pere Virgili IISPV, Tarragona, Spain; Medicine and Surgery Department, Faculty of Medicine, Universitat Rovira i Virgili, Tarragona, Spain.

Eduardo Lehrer (E)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.

Izaskun Valduvieco (I)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Radiation Oncology Department, Hospital Clínic, Barcelona, Spain.

Neus Baste (N)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Translational Genomics and Target Therapies in Solid Tumors Group, Institut d́Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain.

Rosa Delia Ramírez (R)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain.

José Miguel Costa (J)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.

Santiago Medrano-Martorell (S)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Radiology Department, Hospital Clínic, Barcelona, Spain.

África Muxí (Á)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain.

Paola Castillo (P)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Pathology Department, Hospital Clínic, Barcelona, Spain.

Llúcia Alós (L)

Functional Unit of Head and Neck Tumors, Hospital Clínic, Barcelona, Spain; Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Pathology Department, Hospital Clínic, Barcelona, Spain.

Manuel Bernal-Sprekelsen (M)

Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH